Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Population decline

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    131 result(s) found for: Population decline. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2020-000595-37 Sponsor Protocol Number: 1111111 Start Date*: 2020-12-02
    Sponsor Name:Fakultní nemocnice v Motole
    Full Title: Pharmacokinetics and pharmacodynamics of levobupivacaine during continuous caudal epidural analgesia in newborns
    Medical condition: The primary aim of study is to determine PK and PD of levobupivacaine in newborns (premature included). And discover or decline of LA cumulation. The secondary aim of the study is to obtain enough ...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003903-16 Sponsor Protocol Number: LPS16676 Start Date*: 2022-02-14
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Placebo controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients with Uncontrolled Moderate to Severe Asthma (ATLAS)
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001436-35 Sponsor Protocol Number: COFITAGE2016 Start Date*: 2017-01-06
    Sponsor Name:Service of Neurology, CHU Liege
    Full Title: How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly population
    Medical condition: Healthy middle aged (50 - 70 y.o.) individual with and without preclinical Alzheimer's disease defined by biomarkers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001265-36 Sponsor Protocol Number: UCDCRC/20/01 Start Date*: 2020-05-05
    Sponsor Name:University College Dublin
    Full Title: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the ...
    Medical condition: SARS-CoV-2 PCR-positive population
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002725-74 Sponsor Protocol Number: COU-AA-004 Start Date*: 2007-07-16
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
    Medical condition: HRPC (Hormone refractory prostate cancer) refractory to androgen deprivation and Docetaxel based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002277-22 Sponsor Protocol Number: AMYPAD-02 Start Date*: 2018-09-12
    Sponsor Name:Stichting VUmc
    Full Title: AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid im...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004454-42 Sponsor Protocol Number: DIABMIND Start Date*: 2018-04-27
    Sponsor Name:Vall d'Hebron Research Institute
    Full Title: English A pilot interventional study to arrest the progression of cognitive decline in diabetic patients at high risk of developing Alzheimer's disease by reducing hypoglycemic events.
    Medical condition: Cognitive decline in patients affected with mild cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10012267 Dementia PT
    20.1 100000004861 10021005 Hypoglycemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003205-66 Sponsor Protocol Number: MedOPP293 Start Date*: 2022-01-17
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2)
    Medical condition: HER2-Positive Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000931-15 Sponsor Protocol Number: ICR-CTSU/2016/10060 Start Date*: 2018-07-02
    Sponsor Name:Institute of Cancer Research
    Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003896-24 Sponsor Protocol Number: D169AC00001 Start Date*: 2017-01-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
    Medical condition: Chronic kidney disease (CKD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Completed) DE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004571-36 Sponsor Protocol Number: COU-AA-003 Start Date*: 2006-10-23
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004091-34 Sponsor Protocol Number: CCR3972 Start Date*: 2014-03-26
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Reseacrh
    Full Title: A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer
    Medical condition: Metastatic Castration- Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-005118-37 Sponsor Protocol Number: H6L-MC-LFAN (e) Start Date*: 2008-12-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) FI (Completed) ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) GR (Prematurely Ended) SE (Prematurely Ended) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001617-27 Sponsor Protocol Number: IVA_01_337_HSSC_15_001 Start Date*: 2015-09-18
    Sponsor Name:Inventiva SAS
    Full Title: A randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis
    Medical condition: Systemic sclerosis (scleroderma) (SSc) is a chronic connective tissue disorder of unknown aetiology characterized by widespread microvascular damage and excessive deposition of collagen in the skin...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10012941 Diffuse scleroderma LLT
    18.0 100000004859 10074034 Generalised scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed) DE (Completed) NL (Completed) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-006032-22 Sponsor Protocol Number: 41829447 (ISRCTN No) Start Date*: 2007-04-04
    Sponsor Name:University of Manchester [...]
    1. University of Manchester
    2. Dudley Group of Hospitals NHS Trust
    Full Title: TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their chole...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001564-21 Sponsor Protocol Number: GN09CP301 Start Date*: 2011-09-19
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study)
    Medical condition: Alzheimer's disease Down syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000574-40 Sponsor Protocol Number: PSP-CoQ10 Start Date*: 2006-04-24
    Sponsor Name:Kompetenznetz Parkinson e.V.
    Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon®
    Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001348-24 Sponsor Protocol Number: 3004 Start Date*: 2012-09-10
    Sponsor Name:Joslin Diabetes Center
    Full Title: A pilot study of allopurinol to prevent GFR loss in type 1 diabetes
    Medical condition: Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004577-30 Sponsor Protocol Number: EARLY-GENE Start Date*: 2022-03-11
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO MAJADAHONDA
    Full Title: EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial)
    Medical condition: Dilated Cardiomyopathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003390-95 Sponsor Protocol Number: WN28745 Start Date*: 2014-02-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease: Part II: Open-label exten...
    Medical condition: MILD ALZHEIMER’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) ES (Completed) PT (Completed) IT (Completed) NL (Completed) BE (Completed) HU (Completed) FI (Completed) BG (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 01:32:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA